Document Detail


XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.
MedLine Citation:
PMID:  18069904     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study. OBJECTIVE: To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis. DESIGN: XP-828L 5 g/d (group A, n=42) or placebo (group B, n=42) was given orally for 56 days followed by XP-828L 5 g/d in group A and by XP-828L 10 g/d in group B for an additional 56 days. RESULTS: Patients receiving XP-828L 5 g/d for 56 days had an improved Physician's Global Assessment (PGA) score compared with patients under placebo (p less than 0.05). Considering the data of group A only, the PGA score improved from day 1 to day 56 (p less than 0.01); the Psoriasis Area and Severity Index score improved as well, but to a lesser extent (p less than 0.05). CONCLUSION: Oral administration of 5 g/d XP-828L compared with a placebo significantly improved the PGA score of patients with mild to moderate psoriasis.
Authors:
Yves Poulin; Robert Bissonnette; Christina Juneau; Kim Cantin; Rejean Drouin; Patrice E Poubelle
Related Documents :
11952534 - Topical preparations for the treatment of psoriasis: a systematic review.
17014654 - Successful treatment of pediatric psoriasis with indigo naturalis composite ointment.
23650124 - A novel approach to identify responder subgroups and predictors of response to low- and...
20000874 - Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label ...
16781604 - The effect of ginkgo biloba on functional measures in multiple sclerosis: a pilot rando...
18334054 - Sublingual immunotherapy for latex allergy: tolerability and safety profile of rush bui...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Alternative medicine review : a journal of clinical therapeutic     Volume:  12     ISSN:  1089-5159     ISO Abbreviation:  Altern Med Rev     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-11     Completed Date:  2008-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705340     Medline TA:  Altern Med Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  352-9     Citation Subset:  K    
Affiliation:
Department of Medicine, Laval University, Quebec City, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Analysis of Variance
Dermatologic Agents / adverse effects,  therapeutic use*
Double-Blind Method
Female
Humans
Male
Middle Aged
Milk Proteins / adverse effects,  therapeutic use*
Psoriasis / drug therapy*,  pathology
Quebec
Severity of Illness Index
Chemical
Reg. No./Substance:
0/Dermatologic Agents; 0/Milk Proteins; 0/XP-828l

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy hum...
Next Document:  The accidental mentor: Australian rural nurses developing supportive relationships in the workplace.